Regeneron: Dupixent expansion meets Eylea patent cliff - Biotech quality test
Scores at time of recommendation (January 31, 2026)
5-year stock timeline
Regeneron (REGN) has traced a distinct five-year arc from pandemic windfall to product-led compounder, with the stock now trading at 627.74 as of late May 2026.
The COVID chapter and its reversal
REGEN-COV arrived as a major inflection point in late 2020. The company rapidly developed the monoclonal antibody, secured Emergency Use Authorization, and delivered nearly 3 million doses to the U.S. government through 2021. For investors, it was the definition of a tailwind—both revenue and sentiment accelerated sharply. That momentum carried through 2021 as the stock participated in a broad biotech rally and genuine clinical execution.
Then Omicron arrived. In January 2022, management announced REGEN-COV would be largely ineffective against the variant. The FDA restricted the EUA, and Regeneron took inventory write-downs while guiding materially lower COVID antibody revenues. The narrative flipped overnight from hero to cautionary tale. The stock experienced a sharp drawdown with notable volume on the downside; it was a real breakdown moment.
The pivot and consolidation
What happened next mattered more than the COVID setback itself. Rather than chase the fading antibody franchise, management reoriented the investment thesis around existing non-COVID franchises: Dupixent royalties through the Sanofi partnership, the EYLEA ophthalmology business, and emerging oncology assets. From 2022 into early 2024, the stock consolidated as investors waited for proof of concept. Pipeline readouts and quarterly commercial performance became the primary drivers of near-term moves.
The reset upward
By 2024, the thesis had stabilized. Dupixent and EYLEA delivered consistent performance. Regulatory filings and FDA actions—particularly Dupixent review extensions in 2024—provided visible catalysts. The stock began trending higher again as 2025 and 2026 earnings visibility improved and management demonstrated the business could grow sustainably without COVID. That upward pressure has persisted into the current period, reflected in the current price level.
The lesson embedded in this timeline: sentiment can reverse sharply on binary events, but what endures is execution against the core franchise. Regeneron survived the pivot because the underlying assets were real.
Key Points
- Q4 2025: Sales +3% to 3.9 billion USD, adjusted EPS USD 11.44 (consensus USD 10.56) - Dupixent grows 32% to 17.8 bn. USD Annual turnover
- Eylea HD +66% to 506 million USD, while Legacy-Eylea slumps -52% due to biosimilar competition and compounding pressure
- Libtayo 425 million USD (+13% YoY), market leader in advanced forms of skin cancer with expansion into cervical cancer
- Net profit 1.2 billion USD, free cash flow 4.1 billion USD (2025), net liquidity 16.2 bn. USD - 3.4 billion USD Share buybacks
Investment Thesis
Regeneron's Q4 beat shows operational stability driven by Dupixent growth, while Eylea HD only partially compensates for legacy erosion. The pipeline will deliver at least four FDA approvals by the end of 2026, including three new active ingredients, but the patent cliff from 2031 at Dupixent casts a shadow ahead - Sanofi has already admitted that it will not be able to close the sales gap. With a P/E ratio of 17.5, a 31% net margin and solid balance sheet quality (equity ratio 78%), the share is trading below analysts' consensus of USD 832. The valuation reflects both the essential nature of the core products (blindness prevention, severe dermatitis) and structural risks due to Medicare price negotiations and product concentration. For patient investors, the combination of FDA catalysts, institutional buying and quality management offers an interesting entry point - provided the regulatory uncertainties of the Trump era are priced in.
Competitive landscape
Regeneron operates in a densely populated biopharma landscape where it faces established integrated pharmaceutical players and specialized biologics competitors—Amgen, AbbVie, Merck, Bristol-Myers Squibb, Novartis, and Pfizer among them. The regulatory and clinical hurdles in oncology and novel immunotherapies are real; the company is working against entrenched competitors while managing meaningful program risk. What adds pressure is the revenue concentration in a narrow product portfolio. Pricing and reimbursement headwinds compound the challenge, creating meaningful execution and revenue volatility that's worth monitoring.
| Company | Ticker |
|---|---|
| Amgen, Inc. | AMGN.NASDAQ |
| AbbVie Inc. | ABBV.NYSE |
| Merck & Co., Inc. | MRK.NYSE |
| Bristol-Myers Squibb Company | BMY.NYSE |
| Novartis AG | NVS.NYSE |
| Pfizer Inc. | PFE.NYSE |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialCatalysts
- FDA decision on new Eylea HD filler manufacturer in Q2 2026 after Catalent delays
- Dupixent COPD approval (November 2025) and Libtayo cervical cancer expansion each unlock 2+ billion USD peak sales potential
- At least three new molecular entities with FDA approvals in the next 12 months
- GLP-1 agonist data H1 2026 as diversification in obesity market
- Possible agreement with Trump administration on drug prices along the lines of other pharmaceutical companies
Analysis
Performance Figures of Regeneron Pharmaceuticals Inc
Relative Performance vs Benchmarks
| Period | Regeneron Pharmaceuticals Inc | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | -14.09% | -18.80% | -19.54% |
| 3M | -19.57% | -19.03% | -29.27% |
| 6M | -19.32% | -24.82% | -29.76% |
| 1Y | +6.65% | +2.03% | -22.50% |
| 3Y | -12.71% | -70.35% | -98.38% |
| 5Y | +25.97% | -36.07% | -65.33% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 15.3 | 4.5 | 2.2 | 13.5 |
| 1Y ago | 14.9 | 4.8 | 2.3 | 17.0 |
| 3Y ago | 19.8 | 6.7 | 3.5 | 19.3 |
| 5Y ago | 13.7 | 6.0 | 4.6 | 21.2 |
Frequently Asked Questions
Is Regeneron Pharmaceuticals Inc a good investment?
What does Regeneron Pharmaceuticals Inc do?
What are the key metrics for REGN.NASDAQ?
How has Regeneron Pharmaceuticals Inc's stock price performed?
How is REGN.NASDAQ valued?
What are the growth catalysts for Regeneron Pharmaceuticals Inc?
- FDA decision on new Eylea HD filler manufacturer in Q2 2026 after Catalent delays
- Dupixent COPD approval (November 2025) and Libtayo cervical cancer expansion each unlock 2+ billion USD peak sales potential
- At least three new molecular entities with FDA approvals in the next 12 months
- GLP-1 agonist data H1 2026 as diversification in obesity market
- Possible agreement with Trump administration on drug prices along the lines of other pharmaceutical companies
Who are the main competitors of Regeneron Pharmaceuticals Inc?
- Amgen, Inc. (AMGN.NASDAQ)
- AbbVie Inc. (ABBV.NYSE)
- Merck & Co., Inc. (MRK.NYSE)
- Bristol-Myers Squibb Company (BMY.NYSE)
- Novartis AG (NVS.NYSE)
- Pfizer Inc. (PFE.NYSE)
When does Regeneron Pharmaceuticals Inc report earnings?
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 0.94 USD | 0.15% | 0.14% |
| 2026 | 0.94 USD | 0.12% | |
| 2025 | 0.88 USD | 0.13% | |
| 2025 | 0.88 USD | 0.15% | |
| 2025 | 0.88 USD | 0.15% | |
| 2025 | 0.88 USD | 0.13% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 14.34B | 14.20B | 13.12B | 12.17B | 16.07B |
| Operating income (EBIT) | 3.58B | 3.99B | 4.05B | 5.39B | 9.00B |
| Net income | 4.50B | 4.41B | 3.95B | 4.34B | 8.08B |
| Free cash flow | 4.08B | 3.66B | 3.67B | 4.42B | 6.53B |
| Total assets | 40.56B | 37.76B | 33.08B | 29.21B | 25.43B |
| Equity | 31.26B | 29.35B | 25.97B | 22.66B | 18.77B |
| Net debt | -412.20M | 216.20M | -27.10M | -404.50M | -185.90M |
PWP Leeway UG (haftungsbeschränkt)
